Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 7/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18572911 | 1.00 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| SCHEMBL17034800 | 1.00 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| Hydrochloric Acid SCHEMBL18548455 | 0.99 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| Hydrochloric Acid SCHEMBL17047384 | 0.99 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| Hydrochloric Acid SCHEMBL17023486 | 0.99 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| Hydrochloric Acid SCHEMBL29545426 | 0.99 | CFD (0.40) | CFDKLKB1MEN1KMT2ACHRM1 | |
| SCHEMBL18576584 | 0.86 | KLKB1 (0.37) | CFDKLKB1MEN1KMT2ACYP2C19 | |
| SCHEMBL18546454 | 0.86 | KLKB1 (0.37) | CFDKLKB1MEN1KMT2ACYP2C19 | |
| Hydrochloric Acid SCHEMBL18546403 | 0.85 | KLKB1 (0.36) | CFDKLKB1MEN1KMT2ACYP2C19 | |
| SCHEMBL20687420 | 0.83 | CFD (0.40) | CFDMEN1KMT2ACHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796741-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | CFD 1/4885KLKB1 57/4885MEN1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.